menu
    • menu
    [{"orgOrder":0,"company":"Focus-X Therapeutics","sponsor":"Full-Life Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"NTSR1","moa":"Neurotensin receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Focus-X Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Focus-X Therapeutics \/ Full-Life Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Focus-X Therapeutics \/ Full-Life Technologies"},{"orgOrder":0,"company":"Focus-X Therapeutics","sponsor":"Full-Life Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus-X Therapeutics","amount2":0.25,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Focus-X Therapeutics \/ Focus-X Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Focus-X Therapeutics \/ Focus-X Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Focus-X Therapeutics

    Menu

    Focus-X Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Focus-X Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Focus-X Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Full-Life Technologies

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Ful...

                            Details : Focus-X is developing targeted radiopharmaceuticals-based therapeutic to treat cancer based on its proprietary peptide engineering technology. Viva also provided Focus-X with comprehensive incubation services to help it realize the transformation from co...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 02, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Full-Life Technologies

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Focus-X Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Focus-X Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTSR1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Full-Life Technologies

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipelin...

                            Details : The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : NTSR1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Full-Life Technologies

                            Deal Size : $245.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth